Effectiveness and safety of age-based dosing of abrocitinib in children and adolescents with moderate to severe atopic dermatitis: A two-center, prospective real-world study in China
Abstract
Abrocitinib have been approved for patients with moderate to severe atopic dermatitis (AD), but its effectiveness and safety in adolescents, especially children is not established in both clinical trial and real-world studies. We aimed to analyze real-world data of abrocitinib in the treatment of children and adolescents. We prospectively enrolled children and adolescents with moderate to severe AD from 2 centers, who were stratified based on age groups (<6 years, 6-11 years, 12-17 years) and treated with oral abrocitinib at dosages of 25, 50, or 100 mg daily accordingly. The study assessed various parameters, including the eczema area and severity index (EASI), scoring of atopic dermatitis, investigator's global assessment, numerical rating scale-itch, sleep-loss scores, children dermatology quality of life index/dermatology quality of life index, and safety at baseline and at weeks 2, 4, and 12 of treatment. This study included 28 children and adolescents with moderate to severe AD (4 patients aged < 6 years, 9 aged 6-11 years, and 15 aged 12-17 years). All patients combined exhibited a rapid and significant improvement in the clinical signs and symptoms of AD following the initial follow-up visit. By week 12, EASI-50, EASI-75, and EASI-90 responses were achieved by 100%, 60.7%, and 25.0% of all patients combined, respectively. 57.2% of all patients combined achieved investigator's global assessment 0/1, and 85.7% had a reduction in numerical rating scale-itch score of at…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 28 participants or records.
Read the paper
Related studies
- Artificial Intelligence in Medicine: Cross-Sectional Study Among Medical Students on Application, Education, and Ethical Aspects
- Information quality of videos related to esophageal cancer on tiktok, kwai, and bilibili: a cross-sectional study
- The quality and reliability of short videos about hypertension on TikTok: a cross-sectional study
- Quality and reliability evaluation of pancreatic cancer-related video content on social short video platforms: a cross-sectional study
- Quality and reliability of pediatric pneumonia related short videos on mainstream platforms: cross-sectional study
- Association between metabolic score for insulin resistance (METS-IR) and hypertension: a cross-sectional study based on NHANES 2007–2018
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.